Bristol-Myers Squibb Company Says FDA OKs Supplemental NDA for SUSTIVA

... is a risk of developing HIV resistance if SUSTIVA is underdosed. Bristol-Myers Squibb remains at the forefront of HIV/AIDS research and continues to pursue the development of treatment options for children and adults with HIV. Studies are ongoing ...

http://www.biospace.com/news_story.aspx?StoryID=295220&full=1